S&P 500   4,589.17 (+0.49%)
DOW   34,548.95 (+0.19%)
QQQ   395.67 (+0.47%)
AAPL   169.07 (+2.28%)
MSFT   335.56 (+1.50%)
FB   317.61 (-2.11%)
GOOGL   2,874.86 (+1.30%)
AMZN   3,500.35 (-0.19%)
TSLA   1,138.90 (-0.51%)
NVDA   323.38 (-1.03%)
BABA   125.10 (-1.91%)
NIO   39.62 (+1.25%)
CGC   10.34 (-3.45%)
AMD   154.45 (-2.48%)
GE   95.38 (+0.41%)
MU   87.61 (+4.30%)
T   22.54 (-1.27%)
F   20.05 (+4.48%)
DIS   144.86 (-0.03%)
PFE   54.53 (+1.49%)
ACB   6.22 (-3.12%)
AMC   32.43 (-4.45%)
BA   193.84 (-2.03%)
S&P 500   4,589.17 (+0.49%)
DOW   34,548.95 (+0.19%)
QQQ   395.67 (+0.47%)
AAPL   169.07 (+2.28%)
MSFT   335.56 (+1.50%)
FB   317.61 (-2.11%)
GOOGL   2,874.86 (+1.30%)
AMZN   3,500.35 (-0.19%)
TSLA   1,138.90 (-0.51%)
NVDA   323.38 (-1.03%)
BABA   125.10 (-1.91%)
NIO   39.62 (+1.25%)
CGC   10.34 (-3.45%)
AMD   154.45 (-2.48%)
GE   95.38 (+0.41%)
MU   87.61 (+4.30%)
T   22.54 (-1.27%)
F   20.05 (+4.48%)
DIS   144.86 (-0.03%)
PFE   54.53 (+1.49%)
ACB   6.22 (-3.12%)
AMC   32.43 (-4.45%)
BA   193.84 (-2.03%)
S&P 500   4,589.17 (+0.49%)
DOW   34,548.95 (+0.19%)
QQQ   395.67 (+0.47%)
AAPL   169.07 (+2.28%)
MSFT   335.56 (+1.50%)
FB   317.61 (-2.11%)
GOOGL   2,874.86 (+1.30%)
AMZN   3,500.35 (-0.19%)
TSLA   1,138.90 (-0.51%)
NVDA   323.38 (-1.03%)
BABA   125.10 (-1.91%)
NIO   39.62 (+1.25%)
CGC   10.34 (-3.45%)
AMD   154.45 (-2.48%)
GE   95.38 (+0.41%)
MU   87.61 (+4.30%)
T   22.54 (-1.27%)
F   20.05 (+4.48%)
DIS   144.86 (-0.03%)
PFE   54.53 (+1.49%)
ACB   6.22 (-3.12%)
AMC   32.43 (-4.45%)
BA   193.84 (-2.03%)
S&P 500   4,589.17 (+0.49%)
DOW   34,548.95 (+0.19%)
QQQ   395.67 (+0.47%)
AAPL   169.07 (+2.28%)
MSFT   335.56 (+1.50%)
FB   317.61 (-2.11%)
GOOGL   2,874.86 (+1.30%)
AMZN   3,500.35 (-0.19%)
TSLA   1,138.90 (-0.51%)
NVDA   323.38 (-1.03%)
BABA   125.10 (-1.91%)
NIO   39.62 (+1.25%)
CGC   10.34 (-3.45%)
AMD   154.45 (-2.48%)
GE   95.38 (+0.41%)
MU   87.61 (+4.30%)
T   22.54 (-1.27%)
F   20.05 (+4.48%)
DIS   144.86 (-0.03%)
PFE   54.53 (+1.49%)
ACB   6.22 (-3.12%)
AMC   32.43 (-4.45%)
BA   193.84 (-2.03%)
NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$2.30
-0.07 (-2.95%)
(As of 12/1/2021 01:31 PM ET)
Add
Compare
Today's Range
$2.26
$2.39
50-Day Range
$2.23
$3.02
52-Week Range
$2.17
$5.50
Volume
12,021 shs
Average Volume
519,599 shs
Market Capitalization
$33.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.51
30 days | 90 days | 365 days | Advanced Chart
Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.


ARCA biopharma logo

About ARCA biopharma

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Headlines

Short Interest in ARCA biopharma, Inc. (NASDAQ:ABIO) Grows By 54.1%
December 1, 2021 |  americanbankingnews.com
Financial Review: ARCA biopharma (ABIO) versus The Competition
November 30, 2021 |  americanbankingnews.com
Comparing ARCA biopharma (ABIO) & Its Peers
November 29, 2021 |  americanbankingnews.com
Critical Comparison: ARCA biopharma (ABIO) and Its Rivals
November 27, 2021 |  americanbankingnews.com
Head-To-Head Contrast: ARCA biopharma (ABIO) and The Competition
November 25, 2021 |  americanbankingnews.com
Financial Contrast: ARCA biopharma (ABIO) vs. Its Rivals
November 24, 2021 |  americanbankingnews.com
Head to Head Survey: ARCA biopharma (ABIO) & Its Competitors
November 23, 2021 |  americanbankingnews.com
Reviewing ARCA biopharma (ABIO) and Its Peers
November 21, 2021 |  americanbankingnews.com
Head to Head Survey: ARCA biopharma (ABIO) vs. Its Rivals
November 19, 2021 |  americanbankingnews.com
Head-To-Head Contrast: ARCA biopharma (ABIO) & Its Peers
November 19, 2021 |  americanbankingnews.com
ARCA biopharma (ABIO) and Its Competitors Head-To-Head Survey
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.87 per share

Profitability

Net Income
$-9.74 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,341,000
Market Cap
$33.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/17/2022

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

1165th out of 1,392 stocks

Diagnostic Substances Industry

19th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

How has ARCA biopharma's stock price been impacted by Coronavirus (COVID-19)?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABIO shares have decreased by 31.5% and is now trading at $2.30.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 450,700 shares, an increase of 54.1% from the October 31st total of 292,500 shares. Based on an average daily volume of 358,500 shares, the days-to-cover ratio is currently 1.3 days. Currently, 3.1% of the company's shares are sold short.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for ARCA biopharma
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.33) earnings per share for the quarter.
View ARCA biopharma's earnings history
.

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Michael R. Bristow, President, Chief Executive Officer & Director
  • Thomas A. Keuer, Chief Operating Officer
  • C. Jeffrey Dekker, Chief Financial Officer
  • Debra Marshall, Chief Medical Officer
  • Christopher David Ozeroff, Secretary, Senior Vice President & General Counsel

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (3.07%), BlackRock Inc. (1.86%), Geode Capital Management LLC (0.66%), Citadel Advisors LLC (0.00%), Millennium Management LLC (0.11%) and Minerva Advisors LLC (0.07%). Company insiders that own ARCA biopharma stock include Christopher David Ozeroff and Robert E Conway.
View institutional ownership trends for ARCA biopharma
.

Which institutional investors are selling ARCA biopharma stock?

ABIO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for ARCA biopharma
or view top insider-selling stocks.

Which institutional investors are buying ARCA biopharma stock?

ABIO stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Citadel Advisors LLC, Millennium Management LLC, Minerva Advisors LLC, and Geode Capital Management LLC. Company insiders that have bought ARCA biopharma stock in the last two years include Christopher David Ozeroff, and Robert E Conway.
View insider buying and selling activity for ARCA biopharma
or or view top insider-buying stocks.

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.30.

How much money does ARCA biopharma make?

ARCA biopharma has a market capitalization of $33.14 million. The biopharmaceutical company earns $-9.74 million in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does ARCA biopharma have?

ARCA biopharma employs 13 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is arcabio.com.

Where are ARCA biopharma's headquarters?

ARCA biopharma is headquartered at 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at (720) 940-2200, via email at [email protected], or via fax at 720-208-9261.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.